Accessible Search Form           Advanced Search

Dr. Hoots In The News

September 9, 2014
NIH-convened panel recommends expanded adoption of drug and transfusion treatments for individuals with sickle cell disease
An expert panel has recommended expanded adoption of the drug hydroxyurea for the care of people with sickle cell disease, according to a report issued today. The report also suggests that clinicians give periodic blood transfusions to children with the disease to reduce stroke risk. According to the panel, both treatments are underutilized.

September 14, 2012 : Circulation Research
On the value of portfolio diversity in heart, lung, and blood research
Zorina S. Galis, Ph.D., W. Keith Hoots, M.D., James P. Kiley, Ph.D., and Michael S. Lauer, M.D., NHLBI
Just as in other fields, scientific diversity has been and continues to be critical for the success of HLB research.

August 13, 2012 : Circulation Research
Editorial: On the value of portfolio diversity in heart, lung, and blood research
coauthored by Zorina S. Galis, Ph.D., W. Keith Hoots, M.D., James P. Kiley, Ph.D., and Michael Lauer, M.D., NHLBI
This editorial examines the diversity of topics and mechanisms in the NHLBI portfolio.

November 25, 1998
Statement from Claude Lenfant, M.D., NHLBI Director, On Umbilical Cord Blood Transplantation
Although it is a relatively new therapy, bone marrow transplantation has become a routine treatment for patients with a variety of genetic disorders and blood diseases.

September 16, 1997
NHLBI to Announce Sickle Cell Clinical Alert at Press Conference
The National Heart, Lung, and Blood Institute (NHLBI) will hold a press conference on Thursday, September 18, 1997, at 10:00 a.m. to announce the results of an important clinical trial involving the prevention of strokes in children with sickle cell anemia.

Return to Dr. Hoots's Biography

Last Updated: April 12, 2012